Thank you for submitting your question. You will get a reply
within two business days to the email you provided.
Something went wrong. Please submit again.
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
24 April, 2013
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information